Deal Details

Natera Completes $585 Million Follow-On Offering

Healthcare

Natera follow-on offering

Summary

Natera, Inc. (“Natera” or the “Company”) (NASDAQ-GS:NTRA) recently completed an upsized underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $113.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 675,000 shares of common stock. The gross proceeds to Natera from the offering are expected to be approximately $584.8 million before deducting the underwriting discounts and commissions.

Baird served as a co-manager on this offering.

About

Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the Company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Natera offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Natera, Inc. is headquartered in San Carlos, California.

Healthcare

Natera follow-on offering